In Publikationen
,
back BACK
Novel fully human high-affi­nity anti-TREM2 anti­body shows effi­cacy in cli­ni­cally rele­vant Alzheimer’s mouse model.
Loss of TREM2 res­cues hyperac­ti­va­tion of micro­glia, but not lys­o­so­mal defi­cits and neu­ro­to­xi­city in models of pro­gra­nu­lin deficiency.